MX2022002489A - Composiciones de neurotoxinas para usarse en el tratamiento contra cefalea. - Google Patents

Composiciones de neurotoxinas para usarse en el tratamiento contra cefalea.

Info

Publication number
MX2022002489A
MX2022002489A MX2022002489A MX2022002489A MX2022002489A MX 2022002489 A MX2022002489 A MX 2022002489A MX 2022002489 A MX2022002489 A MX 2022002489A MX 2022002489 A MX2022002489 A MX 2022002489A MX 2022002489 A MX2022002489 A MX 2022002489A
Authority
MX
Mexico
Prior art keywords
treating headache
neurotoxin compositions
compositions
methods
neurotoxin
Prior art date
Application number
MX2022002489A
Other languages
English (en)
Inventor
Gregory F Brooks
Andrew M Blumenfeld
Original Assignee
Aeon Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeon Biopharma Inc filed Critical Aeon Biopharma Inc
Publication of MX2022002489A publication Critical patent/MX2022002489A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se describen composiciones y métodos para usarse en el tratamiento contra la jaqueca, por ejemplo, jaqueca episódica o crónica, que incluyen métodos con efectos secundarios reducidos y eficacia comparable o mejorada en comparación con métodos conocidos en la materia.
MX2022002489A 2019-08-30 2020-08-28 Composiciones de neurotoxinas para usarse en el tratamiento contra cefalea. MX2022002489A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962894540P 2019-08-30 2019-08-30
US201962950775P 2019-12-19 2019-12-19
US202063011168P 2020-04-16 2020-04-16
US202063029304P 2020-05-22 2020-05-22
PCT/US2020/048624 WO2021041978A1 (en) 2019-08-30 2020-08-28 Neurotoxin compositions for use in treating headache

Publications (1)

Publication Number Publication Date
MX2022002489A true MX2022002489A (es) 2022-03-22

Family

ID=74682011

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002489A MX2022002489A (es) 2019-08-30 2020-08-28 Composiciones de neurotoxinas para usarse en el tratamiento contra cefalea.

Country Status (10)

Country Link
US (2) US11826405B2 (es)
EP (1) EP4022054A4 (es)
JP (1) JP2022546517A (es)
KR (1) KR20220054371A (es)
AU (1) AU2020340428A1 (es)
CA (1) CA3152024A1 (es)
IL (1) IL290996A (es)
MX (1) MX2022002489A (es)
WO (1) WO2021041978A1 (es)
ZA (1) ZA202202302B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018175688A1 (en) * 2017-03-22 2018-09-27 Bonti, Inc. Botulinum neurotoxins for use in therapy
AU2020340428A1 (en) 2019-08-30 2022-03-03 AEON Biopharma, Inc. Neurotoxin compositions for use in treating headache
US10960061B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
US10967052B1 (en) 2019-10-18 2021-04-06 Penland Foundation Treatment of dyslexia using botulinum toxin
CA3212003A1 (en) * 2021-02-26 2022-09-01 AEON Biopharma, Inc. Neurotoxin compositions for use in treating headache
WO2023287729A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of acute and chronic kidney disease
WO2023287728A1 (en) * 2021-07-12 2023-01-19 Penland Foundation Treatment of diabetes and chronic pancreatitis using botulinum toxin
KR20240047418A (ko) * 2021-08-12 2024-04-12 이온 바이오파마, 인크. 일회용 신경독 제형 및 패키징
WO2023201358A2 (en) * 2022-04-15 2023-10-19 AEON Biopharma, Inc. Neurotoxin compositions for use in regulating brain temperature

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE292977T1 (de) * 1994-05-09 2005-04-15 William J Binder Präsynaptische neurotoxine gegen migränekopfschmerzen
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US7749515B2 (en) * 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US8666498B2 (en) * 2008-10-27 2014-03-04 Serene Medical, Inc. Treatment of headache
US8940308B2 (en) 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
US10111938B2 (en) 2011-03-30 2018-10-30 Allergan, Inc. Injection paradigm for administration of botulinum toxins
US8491917B1 (en) 2012-03-12 2013-07-23 William J. Bender Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the head
AU2018290765A1 (en) 2017-06-26 2020-01-23 Bonti, Inc. Clostridial neurotoxin formulations and use
WO2019068888A1 (en) * 2017-10-06 2019-04-11 Ranoux Daniele USE OF BOTULINUM TOXIN FOR THE TREATMENT OF SUBJECTIVE ACOUPHENES
AU2020340428A1 (en) 2019-08-30 2022-03-03 AEON Biopharma, Inc. Neurotoxin compositions for use in treating headache

Also Published As

Publication number Publication date
AU2020340428A1 (en) 2022-03-03
JP2022546517A (ja) 2022-11-04
ZA202202302B (en) 2023-07-26
WO2021041978A1 (en) 2021-03-04
IL290996A (en) 2022-05-01
KR20220054371A (ko) 2022-05-02
EP4022054A4 (en) 2023-09-06
US20240050540A1 (en) 2024-02-15
US11826405B2 (en) 2023-11-28
CA3152024A1 (en) 2021-03-04
US20210060144A1 (en) 2021-03-04
EP4022054A1 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
MX2022002489A (es) Composiciones de neurotoxinas para usarse en el tratamiento contra cefalea.
MX2023009867A (es) Composiciones de neurotoxina para usarse en el tratamiento del dolor de cabeza.
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
PH12019501393A1 (en) Afucosylated anti-fgfr2iiib antibodies
EP4339287A3 (en) Modified cells and methods of therapy
TW201713698A (en) PD-1 antibodies
WO2017079570A3 (en) Splise-switching oligonucleotides and methods of use
NZ739133A (en) Cellular targeted active ingredient delivery system
MX2023010206A (es) Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario.
WO2016164401A8 (en) Treatment of lung cancer with inhibitors of glutaminase
MX2021014472A (es) Moleculas de union a tigit y pd-1/tigit.
MA40460A (fr) Ciblage lysosomial et utilisation correspondante
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
PH12017500615B1 (en) Ophthalmic composition comprising cyclosporine and trehalose
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
ZA202209970B (en) Neurotoxin compositions for use in treating cardiovascular disorders
MX2019006552A (es) Terapia génica para mucopolisacaridosis de tipo i.
WO2019075216A8 (en) Plectin-1 binding antibodies and uses thereof
MX2022002367A (es) Composiciones de neurotoxinas para usarse en el tratamiento de neurologicos y trastornos psiquiatricos.
WO2018081817A3 (en) Targeting microrna-101-3p in cancer therapy
AU2015267160A8 (en) Methods and compositions for preventing ischemia reperfusion injury in organs
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX2019009293A (es) Compuestos, composiciones y usos de los mismos para la mejoria de trastornos oseos.